These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 4071435)

  • 21. [Immunology in internal medicine. 2. Immune complexes and diseases].
    Morito T
    Nihon Naika Gakkai Zasshi; 1988 Oct; 77(10):1498-501. PubMed ID: 3243990
    [No Abstract]   [Full Text] [Related]  

  • 22. [Clinical and immunological characteristics of primary and secondary antiphospholipid syndrome].
    Sulut'ian AE; Chapaeva NN; Shirinskiĭ VS; Kozhevnikov VS; Kozlov VA
    Klin Med (Mosk); 2004; 82(8):39-43. PubMed ID: 15468724
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Treatment of systemic lupus erythematosus with antimetabolites. Relations between the clinical course and immunological reactions].
    Cruchaud A; Pometta D; Rousso C
    Helv Med Acta Suppl; 1967 May; 47():141-2. PubMed ID: 5315493
    [No Abstract]   [Full Text] [Related]  

  • 24. Lupus erythematosus panniculitis (profundus).
    Tuffanelli DL
    Arch Dermatol; 1971 Mar; 103(3):231-42. PubMed ID: 4100949
    [No Abstract]   [Full Text] [Related]  

  • 25. [Effect of treatment with enkorton and cytostatics on selected immunologic indicators in patients with systemic lupus erythematosus].
    Małdykowa H; Chwalińska-Sadowska H; Grabowska A; Dratwianka B; Abgarowicz-Miłkowska T; Jedryka-Góral A; Swierczyńska Z; Rdułtowska H; Luft S; Rogozińska E
    Reumatologia; 1982; 20(1-2):7-14. PubMed ID: 7163667
    [No Abstract]   [Full Text] [Related]  

  • 26. Complement-mediated solubilization of immune complexes in systemic lupus erythematosus.
    Sakurai T; Fujita T; Kono I; Kabashima T; Yamane K; Tamura N; Kashiwagi H
    Clin Exp Immunol; 1982 Apr; 48(1):37-42. PubMed ID: 6979449
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The value of three immune complex assays in the management of systemic lupus erythematosus: an assessment of immune complex levels, size and immunochemical properties in relation to disease activity and manifestations.
    Cairns SA; London A; Mallick NP
    Clin Exp Immunol; 1980 May; 40(2):273-82. PubMed ID: 7438538
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Flow cytometric determination of circulating immune complexes with the indirect granulocyte phagocytosis test.
    Terstappen LW; de Grooth BG; Nolten GM; ten Napel CH; van Berkel W; Greve J
    Cytometry; 1985 Jul; 6(4):316-20. PubMed ID: 4017797
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Determination of immune complexes in renal diseases (author's transl)].
    Smolen JS; Wolf A; Scherak O; Syre G; Pinggera W; Stummvoll HK; Leithner C; Menzel EJ
    Acta Med Austriaca; 1981; 8(2):37-41. PubMed ID: 6456639
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Objective evaluation of remote results of treatment of systemic lupus erythematosus].
    Ivanova MM; Nasonova VA; Folomeeva OM; Speranskiĭ AI; Kozlova VN
    Ter Arkh; 1977; 49(9):60-6. PubMed ID: 929421
    [No Abstract]   [Full Text] [Related]  

  • 31. Genetic determination of phagocytic activity of polymorphonuclear leucocytes.
    Zalkovicová M; Buc M; Niks M; Stefanovic J
    Folia Biol (Praha); 1988; 34(4):240-7. PubMed ID: 3071479
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phagocytosis and degradation of DNA-anti-DNA complexes by human phagocytes: influence of the antibody class.
    Lamers MC; de Groot ER; Roos D
    Lab Invest; 1982 Apr; 46(4):393-9. PubMed ID: 7070053
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of azathioprine in autoimmune thrombocytopenia and lupus erythematosus.
    Goebel KM; Gassel WD; Goebel FD
    Scand J Haematol; 1973; 10(1):28-34. PubMed ID: 4735696
    [No Abstract]   [Full Text] [Related]  

  • 34. The significance of immunofluorescent immunoglobulin inclusions in polymorphonuclear leucocytes for the detection of circulating immune complexes.
    Kauffmann RH; de Rooy-Dijk HH; Klein F; Lafeber GJ; Cats A; van Es LA
    Clin Exp Immunol; 1983 Oct; 54(1):203-12. PubMed ID: 6311469
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Therapy of lupus nephritis in childhood].
    Taubert M; Döring E
    Padiatr Grenzgeb; 1983; 22(2-3):191-4. PubMed ID: 6888932
    [No Abstract]   [Full Text] [Related]  

  • 36. [Circulating immune complexes and their degradation in bullous pemphigoid and systemic lupus erythematosus].
    Haustein UF; Lohrisch I; Herrmann K
    Vestn Dermatol Venerol; 1983 Apr; (4):18-21. PubMed ID: 6408824
    [No Abstract]   [Full Text] [Related]  

  • 37. [Immunologic analysis of the effectiveness of hemosorption in symptomatic hypertension of renal origin].
    Rakhmedov D; Osipov SG; Kutsenko AI; Rudnev VI; Bakhov NI
    Ter Arkh; 1985; 57(10):72-5. PubMed ID: 2934847
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Circulating immune complexes (PEG tests) in systemic lupus erythematosus].
    Ivanova MM; Nasonov EL; Solov'ev SK; Speranskiĭ AI; Sura VV
    Ter Arkh; 1982; 54(6):63-8. PubMed ID: 7112424
    [No Abstract]   [Full Text] [Related]  

  • 39. [Circulating immune complexes and C3 in patients with systemic lupus erythematosus. The relationship between clinical manifestations and nephropathy (author's transl)].
    Rodríguez-Valverde V; Peña Sagredo JL; Orte Martínez J; Novo Fernández MJ; Sánchez Andrada S; Sampedro Alvarez J
    Med Clin (Barc); 1982 May; 78(9):353-7. PubMed ID: 6808263
    [No Abstract]   [Full Text] [Related]  

  • 40. Lupus nephritis: clinical course in relation to treatment.
    Nanra RS; Kincaid-Smith P
    Perspect Nephrol Hypertens; 1973; 1 Pt 2(0):1193-210. PubMed ID: 4803309
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.